Company Description

Xilis is developing next-generation ex-vivo technologies that provide a reliable, functional, patient-derived model that can accelerate and de-risk innovation in cancer treatment. Their MOS® Platform is a novel, end-to-end solution that creates and utilizes 3D patient tissue models to provide insights into drug efficacy, clinical utility, and patient selection strategy.